CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
soluble ferric pyrophosphate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01920854
NCT01920854Phase 1Completed
CompareCT.gov

A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Intravenously Administered SFP in Healthy Volunteers

Rockwell Medical Technologies, Inc.·interventional·Posted Aug 12, 2013·Updated Jan 26, 2015

In Brief

A Phase 1 clinical trial evaluating soluble ferric pyrophosphate and Placebo for Kidney Failure, Chronic Therapy; Hemodialysis. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the pharmacokinetics of fixed ascending doses of intravenously administered Soluble Ferric Pyrophosphate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Chronic Therapy; Hemodialysis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 12, 2013
Enrollment StartJun 1, 2013
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.9 years ago

Interventions

soluble ferric pyrophosphatedrug

Placebodrug